Garadacimab

Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa) . Garadacimab has the potential for hereditary angioedema research[1].

Product Specifications

CAS Number

[2162134-62-3]

Product Name Alternative

CSL312

UNSPSC

12352203

Target

Factor Xa

Type

Inhibitory Antibodies

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/garadacimab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Garadacimab]

Molecular Weight

(146.5 kDa)

References & Citations

[1]Dipti Pawaskar, et al. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312) . Clin Transl Sci. 2022 Mar;15 (3) :709-720. |[2]Helen Cao, et al. Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation. J Allergy Clin Immunol. 2018 Oct;142 (4) :1355-1358.